Andrographis for Immune Support: What the Research Shows

Andrographis (Andrographis paniculata) has been used in Ayurvedic and traditional Chinese medicine for centuries, earning the nickname "king of bitters" for its intensely unpleasant flavor. In much of Southeast Asia and India, it's a frontline response to fever and upper respiratory infections. In Scandinavia, it's available as a regulated herbal medicinal product for cold and flu. In the United States, it's barely on most people's radar.

That under-the-radar status doesn't reflect the quality of the evidence. Andrographis has a stronger body of clinical trial data for cold treatment than many far better-known supplements.

The active compound: andrographolide

The primary bioactive in andrographis is andrographolide, a diterpenoid lactone that accounts for 0.5–6% of the dry herb weight (higher in leaves and aerial parts than in roots). Andrographolide has well-characterized mechanisms:

• NF-kB inhibition: Andrographolide suppresses NF-kB activation, reducing pro-inflammatory cytokine production (TNF-alpha, IL-1beta, IL-6)
• Antiviral activity: Cell studies demonstrate activity against influenza viruses, adenoviruses, and coronaviruses by interfering with viral RNA replication
• Immune modulation: Enhances natural killer cell activity and interferon production
• Anti-inflammatory signaling: Inhibits COX-2 and iNOS expression in macrophages

In practice, this translates to immune-supportive and anti-inflammatory effects that are relevant both for cold duration and symptom severity.

The Kaloba trials: what the clinical evidence shows

The most clinically meaningful evidence uses Kaloba, a proprietary A. paniculata extract standardized to 5mg andrographolide per 400mg tablet. Kaloba has regulatory approval in several European countries as a medicinal product for uncomplicated URTIs.

2004 Scandinavian trial (Saxena et al., Phytomedicine): 223 adults with uncomplicated URTIs were randomized to Kaloba or placebo for 5 days. The Kaloba group showed significantly greater reduction in symptom severity across all measured outcomes: sore throat, runny nose, headache, fatigue, earache, and fever. The overall symptom score (sum of 5-point visual analog scales) was 50% lower in the Kaloba group by day 5.

2003 trial (Melchior et al., Phytomedicine): 130 adults with acute uncomplicated URTI randomized to Kaloba or placebo. Statistically significant symptom reduction in the active group starting at day 2, with maximum separation at day 4–5.

A systematic review and meta-analysis published in Cochrane Database of Systematic Reviews (2004, updated 2016, Coon & Ernst) concluded that andrographis extract is superior to placebo for treating URTI symptoms, with effect sizes comparable to or exceeding those seen with echinacea in similar trials.

Unlike some herbal trials where "positive" results mean marginally better than placebo, the andrographis trials show clinically meaningful symptom reductions — the kind patients actually notice.

Dosing

Standardized extract (Kaloba or equivalent, standardized to andrographolide content):

• Acute cold/URTI treatment: 200mg extract (providing 10mg andrographolide) three times daily for 5–7 days
• This equates to roughly 600mg of standardized extract per day

Dried herb (non-standardized):

• 4–6g per day of dried aerial parts, divided into 3–4 doses
• Quality control is significantly more difficult with non-standardized material; extract is strongly preferred

Timing: Start at first symptom onset. Evidence is strongest for early use; late-stage treatment trials show smaller effects.

The taste problem — and why capsules matter

"King of bitters" is not hyperbole. Andrographolide is one of the most intensely bitter compounds found in any medicinal plant — several hundred times more bitter than quinine. Traditional preparations involved boiling the herb into a decoction, which most modern users find intolerable.

Capsules and tablets fully mask the bitterness and are the practical delivery method for consistent use. There is no evidence that the bitterness itself is therapeutically important (unlike with gentian, where oral bitterness stimulates digestive reflexes). Choose encapsulated standardized extract and you lose nothing therapeutically.

Who should not use andrographis

Autoimmune conditions: Andrographolide's immune-modulating effects — specifically enhanced NK cell activity and cytokine regulation — could theoretically worsen autoimmune conditions including lupus, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. This is a theoretical concern based on mechanism rather than clinical case reports, but it warrants caution.

Pregnancy: Andrographis demonstrated uterotonic activity in animal studies (capable of stimulating uterine contractions). It should be avoided entirely during pregnancy. There is insufficient safety data for use during lactation.

Hypersensitivity: Rare allergic reactions have been reported, including rash and urticaria. Discontinue if these occur.

Drug interactions: Andrographolide inhibits CYP450 enzymes (notably CYP3A4) and may increase levels of drugs metabolized by this pathway, including many statins, calcium channel blockers, and immunosuppressants. People on these medications should consult a physician.

Andrographolide also has antiplatelet effects and may potentiate anticoagulants (warfarin, apixaban). Separate by at least two weeks before any scheduled surgery.

Comparing andrographis to echinacea for cold treatment

Both have Cochrane-level evidence and similar effect magnitudes. Key practical differences:

| Feature | Andrographis | Echinacea | |---|---|---| | Species consistency | One species with clear evidence | Species variation matters greatly | | Evidence quality | Very consistent trial results | High heterogeneity between studies | | Form | Standardized extract critical | Extract > dried herb | | Taste | Extremely bitter (use capsules) | Mild to moderate | | Safety in autoimmune | Avoid | Avoid | | Pregnancy | Avoid (uterotonic risk) | Generally avoid |

For people who've tried echinacea with limited results, andrographis is a well-supported alternative worth trying during an acute cold.

The bottom line

Andrographis has more consistent clinical trial evidence for cold symptom reduction than most immune supplements. The Scandinavian Kaloba trials show meaningful reductions in sore throat, fatigue, and overall symptom burden within 2–4 days. Use a standardized extract providing at least 10mg andrographolide per dose, take it three times daily at cold onset, and use capsules — the bitterness is genuine and serves no therapeutic purpose. Avoid if you have an autoimmune condition or are pregnant.

---

Track andrographis effectiveness against your cold history and duration data. Use Optimize free.